CD44v6-Driven Nanoparticles Combined with Immune Therapy for Colorectal Cancer
Wednesday, July 16, 2025
3:16 PM - 3:27 PM EDT
Location: 119 B
Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally, driven by therapy resistance, immune evasion, and the complexity of the tumor microenvironment (TME). CD44 variant 6 (CD44v6) is a key driver of CRC aggressiveness, promoting tumor progression, metastasis, and poor therapeutic outcomes. This study introduces an innovative dual-therapy approach: CD44v6-targeted nanoparticles (v6-iri-NPs) for irinotecan delivery, combined with anti-PD-L1 immunotherapy, designed to enhance drug delivery, modulate the TME, and restore anti-tumor immunity.
Learning Objectives:
At the completion of this activity, participants will know
Describe how CD44v6-targeted nanoparticles enhance drug delivery in colorectal cancer
Explain the immune modulation effects of combining irinotecan-loaded nanoparticles with anti-PD-L1
Evaluate preclinical data showing the efficacy of dual therapy in colorectal cancer models
Flávia Castro – Junior Researcher, i3S - Institute for Research and Innovation in Health, University of Porto, Portugal; Carla Oliveira – Principal Investigator, i3S - Institute for Research and Innovation in Health, University of Porto, Portugal; Bruno Sarmento – Principal Investigator, i3S - Institute for Research and Innovation in Health, University of Porto, Portugal
